Company intelligence / Profile preview
Specific Biologics
Toronto, Ontario, Canadaspecificbiologics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Specific Biologics has demonstrated preclinical proof-of-concept for its Dualase® technology across multiple disease models. The company’s approach enables more predictable genetic modifications by creating non-compatible DNA ends, which can result in defined deletions or increased repair frequency. No clinical trial results have been published as of May 2025.
- Therapeutic areas
- GastroenterologyPulmonologyOphthalmologyNeurology
- Modalities
- Gene editing (dual-cleaving nucleases)Precision gene editing technologies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
adMare BioInnovationsJLABS @ TorontoCystic Fibrosis FoundationLumira Ventures
Beyond the preview
Go deeper on Specific Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Specific Biologics.